Filtered By:
Drug: Temodar
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
Emerging Therapies for Glioblastoma
Conclusions and RelevanceGlioblastoma is an aggressive tumor with heterogeneous molecular features and complex host interactions, many of which are amenable to therapeutic intervention. Meaningful treatment advances will depend on identifying agents that target mechanistic vulnerabilities that are relevant to specific subgroups of patients; increasing patient enrollment into clinical trials is essential to accelerate the development of patient-tailored treatments.
Source: JAMA Neurology - November 1, 2014 Category: Neurology Source Type: research
MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway
ConclusionMAPK8 promoted the resistance to TMZ, accelerated cell proliferation and inhibited the apoptosis of glioblastoma cells via activating MAPK signaling pathway.
Source: Biomedicine and Pharmacotherapy - July 24, 2018 Category: Drugs & Pharmacology Source Type: research
Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
CONCLUSION: In summary, TMEM71 expression was increased in GBM and associated with immune response. Our study suggests that TMEM71 may function as an oncogene and serve as a new effective therapeutic target for the treatment of glioma.
PMID: 31180187 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - June 9, 2019 Category: Neuroscience Authors: Wang KY, Huang RY, Tong XZ, Zhang KN, Liu YW, Zeng F, Hu HM, Jiang T Tags: CNS Neurosci Ther Source Type: research
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
CONCLUSIONS: PSQ and MSP appear more prognostic for overall survival than IHC. Strong evidence is not available to draw conclusions with confidence about the best CpG sites or thresholds for quantitative methods. MSP has been studied mainly for CpG sites 76 to 80 and 84 to 87 and PSQ at CpG sites ranging from 72 to 95. A threshold of 9% for CpG sites 74 to 78 performed better than higher thresholds of 28% or 29% in two of three good-quality studies making such comparisons.PMID:33710615 | DOI:10.1002/14651858.CD013316.pub2
Source: Cochrane Database of Systematic Reviews - March 12, 2021 Category: General Medicine Authors: Alexandra McAleenan Claire Kelly Francesca Spiga Ashleigh Kernohan Hung-Yuan Cheng Sarah Dawson Lena Schmidt Tomos Robinson Sebastian Brandner Claire L Faulkner Christopher Wragg Sarah Jefferies Amy Howell Luke Vale Julian P T Higgins Kathreena M Kurian Source Type: research
Overcoming the challenges in the treatment of glioblastoma via nanocarrier based drug delivery approach
CONCLUSION: Broad research is still needed so that these nanocarriers can be used clinically for the welfare of mankind, in the management of glioblastoma, in near future.PMID:34082676 | DOI:10.2174/1381612827666210603152056
Source: Current Pharmaceutical Design - June 4, 2021 Category: Drugs & Pharmacology Authors: Saurabh Mittal Javed Ali Sanjula Baboota Source Type: research
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis
CONCLUSIONS: For treatment of first recurrence of GBM, among people previously treated with surgery and standard chemoradiotherapy, the combination treatments evaluated did not improve overall survival compared with LOM monotherapy and were often associated with a higher risk of severe adverse events. Limited evidence suggested that re-operation with or without re-irradiation and chemotherapy may be suitable for selected candidates. Evidence on second recurrence is sparse. Re-irradiation with or without bevacizumab may be of value in selected individuals, but more evidence is needed.PMID:34559423 | DOI:10.1002/14651858.CD013579.pub2
Source: Cochrane Database of Systematic Reviews - September 24, 2021 Category: General Medicine Authors: Catherine McBain Theresa A Lawrie Ewelina Rogozi ńska Ashleigh Kernohan Tomos Robinson Sarah Jefferies Source Type: research
Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O ‑6‑Methylguanine‑DNA Methyltransferase
CONCLUSION: This very review throws light on recent discoveries, proposed theories, and clinical developments in the field of temozolomide resistance to summarize the complex and intriguing involvement of onco-biological pathways.PMID:35379142 | DOI:10.2174/1871527321666220404180944
Source: CNS and Neurological Disorders Drug Targets - April 5, 2022 Category: Drugs & Pharmacology Authors: Vanishree Rao Gautam Kumar R J A Vibhavari Krishnadas Nandakumar Nanasaheb Thorat Mallikarjuna Rao Chamallamudi Nitesh Kumar Source Type: research
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review
CNS Oncol. 2022 May 23:CNS86. doi: 10.2217/cns-2021-0015. Online ahead of print.ABSTRACTGlioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until t...
Source: Cancer Control - May 23, 2022 Category: Cancer & Oncology Authors: Patrick G McAleavey Gerard M Walls Anthony J Chalmers Source Type: research
Targeting Glioma Cells with Nutraceuticals: Therapeutic Effects Based on Molecular Mechanisms, New Evidence, and Perspectives
Mini Rev Med Chem. 2022 May 31. doi: 10.2174/1389557522666220531151137. Online ahead of print.ABSTRACTGliomas are the most common malignant cancers of the brain that have unregulated proliferation known as a highly invasive tumor. Hence, their relapse rate is high and the prognosis is low. Despite remarkable advances in neuroimaging, neurosurgery, and radiation therapy, they, especially glioblastoma, are highly resistant to treatments including radiotherapy, surgery, and temozolomide chemotherapy. The average survival rate for patients with malignant glioma is still less than two years, accordingly, the search for new trea...
Source: Mini Reviews in Medicinal Chemistry - June 1, 2022 Category: Chemistry Authors: Marziyeh Salami Raziyeh Salami Mohammad-Hossein Aarabi Alireza Mafi Seyedeh Sara Ghorbanhosseini Rana Shafabakhsh Zatollah Asemi Source Type: research
